Adjusted EBITDA is the headline number. This earnings season shows why the bridge matters more
Harrow, Liquidia and CorMedix each reported strong operating metrics beside very different GAAP and guidance pictures. Leaders should judge the bridge between those numbers, not the number on top.
The number everyone quotes, and what sits beneath it
Adjusted EBITDA has become the pharma industry's preferred shorthand for operating health. This quarter's results show how much that shorthand leaves out when it is read alone.
Liquidia is the starkest case. YUTREPIA net product sales reached $222.7 million, up 31% from the second quarter. Adjusted EBITDA rose to $140.5 million, the fifth consecutive quarterly increase. The company also reported a net loss of $236.3 million, driven by a $389.7 million litigation settlement charge. Its $396.1 million cash balance is described as 'prior to settlement payments'. All three numbers are accurate, and none tells the story alone. The bridge from one to the next is the story.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
The real divide this earnings season is runway: who sets the timeline, and who is set by it
Revenue growth, settlements and trial milestones all matter, but the Q3 filings show the balance sheet decides who can act on them at a time of their own choosing.
Litigation is a launch cost, and earnings season is finally pricing it that way
Liquidia's $389.7 million settlement charge and Harrow's guidance reset show that the cost of defending a franchise belongs in the business case, not in a footnote below adjusted EBITDA.
A guidance raise is only as good as who controls the trigger
Q3 guidance moves look alike on a headline but differ in what they say about control. The companies that own their drivers have earned more trust than those waiting on a partner's calendar.